Embriopatía por isotretinoína: Una entidad que puede evitarse

Translated title of the contribution: Isotretinoin embryopathy: An entity that can be avoided

Francisco Cammarata-Scalisi, Dairelis Nieves, Andrea Avendaño, María A Lacruz-Rengel, Karelys Alviárez, Francys Dávila, Izzet Yavuz, Michele Callea

Research output: Contribution to journalArticle

Abstract

Isotretinoin is the most effective drug in the treatment of severe recalcitrant nodulocystic acne. However, treatment with this drug is associated with adverse effects, the most severe being teratogenesis. It has been estimated that 40% of pregnancies exposed to isotretinoin present spontaneous abortion and 35% develop embryopathy. We present the case of a newborn with a history of prenatal exposure to isotretinoin, a clinical entity that can be avoided, with severe congenital defects in the central nervous system and important facial dysmorphisms, with unfavorable clinical course.

Translated title of the contributionIsotretinoin embryopathy: An entity that can be avoided
Original languageSpanish
Pages (from-to)e303-e307
Number of pages5
JournalArchivos Argentinos de Pediatria
Volume116
Issue number2
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint Dive into the research topics of 'Isotretinoin embryopathy: An entity that can be avoided'. Together they form a unique fingerprint.

  • Cite this

    Cammarata-Scalisi, F., Nieves, D., Avendaño, A., Lacruz-Rengel, M. A., Alviárez, K., Dávila, F., Yavuz, I., & Callea, M. (2018). Embriopatía por isotretinoína: Una entidad que puede evitarse. Archivos Argentinos de Pediatria, 116(2), e303-e307. https://doi.org/10.5546/aap.2018.e303